. 2021 Jun 25;12:667718. doi: 10.3389/fmicb.2021.667718

TABLE 1.

Characteristics of study subjects.

				CD4 + T-cell count
				(cells/mm³)
Sample ID	Group	Age at sampling date (years)	Gender	Current	Nadir	ART at sampling date	Total ART duration (years)	Transmission mode
Q-C1	Case	43	Male	440	270	Abacavir/Lamivudine/Dolutegravir	4.4	Heterosexual
Q-C2	Case	48	Female	400	150	Abacavir/Lamivudine/Dolutegravir	8.3	Heterosexual
Q-C3	Case	38	Male	770	344	Tenofovir (TAF)/Emtricitabine/Rilpivirine	6.4	MSM
Q-C4	Case	42	Female	810	530	TDF/Emtricitabine/Rilpivirine	5.1	Heterosexual
Q-C5	Case	43	Female	740	430	TDF/Emtricitabine/Dolutegravir	5.7	Heterosexual
Q-C6	Case	54	Female	690	280	TDF/Emtricitabine/Efavirenz	6.8	Heterosexual
Q-C7	Case	56	Female	800	570	TDF/Emtricitabine/Rilpivirine	5.0	Heterosexual
Q-C8	Case	45	Male	680	300	Abacavir/Lamivudine/Dolutegravir	8.1	Heterosexual
Q-C9	Case	62	Male	330	140	TAF/Emtricitabine/Dolutegravir	8.8	Drug use
Q-C10	Case	38	Female	780	300	Abacavir/Lamivudine/Dolutegravir	7.7	Heterosexual
Q-D2	Case	44	Female	1020	273	Dolutegravir/Abacavir/Lamivudine	20.8	Heterosexual
Q-D3	Case	55	Female	390	170	TDF/Emtricitabine/Dolutegravir	20.7	Blood product
Q-D4	Case	50	Female	970	380	TDF/Emtricitabine/Dolutegravir	10.9	Heterosexual
Q-H1	Control	29	Male	-	-	-	-	-
Q-H2	Control	35	Male	-	-	-	-	-
Q-H3	Control	51	Male	-	-	-	-	-
Q-H4	Control	32	Male	-	-	-	-	-
Q-H5	Control	40	Male	-	-	-	-	-
Q-H6	Control	24	Male	-	-	-	-	-
Q-H7	Control	30	Male	-	-	-	-	-
Q-H8	Control	27	Male	-	-	-	-	-
Q-H9	Control	42	Male	-	-	-	-	-
Q-H10	Control	33	Male	-	-	-	-	-
Q-H11	Control	30	Male	-	-	-	-	-